

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 040283/0183	SERIAL NO. 09/622,544		
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APR 16 12 2001 U.S. PATENT & TRADEMARK OFFICE		APR 16 12 2001 U.S. PATENT & TRADEMARK OFFICE	CH ENTER 1600 1624 Unassigned		
		APR 16 12 2001 U.S. PATENT & TRADEMARK OFFICE	FILING DATE 10/13/2000	GROUP ART UNIT 1600 1624 Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
B.K.	A1	5,281,625	01/94	Zippies et al	514	634	
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
A2	390 925	04/65	Switzerland				No
A3	390 926	04/65	Switzerland				No
A4	390 927	04/65	Switzerland				No
A5	390 928	04/65	Switzerland				No
A6	342 957	12/59	Switzerland				No
A7	345 893	04/60	Switzerland				No
A8	346 879	06/60	Switzerland				No
A9	362 079	05/62	Switzerland				No
A10	393 337	06/65	Switzerland				No
A11	442 298	08/67	Switzerland				No
A12	1,352,161	05/64	France				No
A13	952,194	12/61	London				
A14	1,185,080	03/70	London				
A15	42-21010	10/67	Japan				Abst.
A16	0 525 203	02/93	Europe				
A17	0 199 845	11/86	Europe				
A18	92/15567	09/92	WIPO				
A19	97/29092	08/97	WIPO				
A20	93/14070	07/93	WIPO				
B.K.	A21	97/45108	12/97	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
D.K.	A22	Ganellin et al., "Synthesis of Potent Non-imidazole Histamine H ₃ -Receptor Antagonists", Arch. Pharm. Pharm. Med. Chem., 331:389-394, (1998), Wiley-VCH Verlag GmbH					
EXAMINER		DATE CONSIDERED					
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 040283/0183		SERIAL NO. 09/622, 544	
INFORMATION DISCLOSURE CITATION		(Use several sheets if necessary)		APR 12 2001 U.S. PATENT DOCUMENTS			
				APPLICANT Sarkis Barret KALINDJIAN et al.			
				FILING DATE 10/13/2000		GROUP ART UNIT 1624 Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
D.K.	A23	Decicco et al., "Amide Surrogates of Matrix Metalloproteinase inhibitors: urea and sulfonamide mimics", Bioorganic & Medicinal Chemistry Letters, vol. 7, no. 8, pp. 2331-2336, 1997, The DuPont Merck Pharm. Co.					
	A24	MacPherson et al., "Discovery of CGS 27023A, a Non-Peptide, potent, and orally active stromelysin inhibitor That blocks cartilage degradation in rabbits", J. Med. Chem., 40:2525-2532, 1997, American Chemical Society					
	A25	Wolin et al., "Novel H ₃ receptor antagonists. Sulfonamide homologs of histamine", Bioorganic & Medicinal Chemistry letters 8 (1998) pp.2157-2162, Elsevier Science Ltd.					
	A26	Vollinga et al., "Homologs of Histamine as histamine H ₃ receptor antagonists: a new potent and selective H ₃ Antagonist, 4(5)-(5-Aminopentyl)-1H-imidazole", J. Med. Chem. 1995, 38:266-271, American Chem. Soc.					
	A27	Timmerman, "Histamine H ₃ ligands: just pharmacological tools or potential therapeutic agents?", J. Med. Chem., 1990, 33:4-11, American Chemical Society					
	A28	Stürzebecher et al., "Synthesis and structure-activity relationship of potent thrombin inhibitors: piperazines of 3-amidinophenylalanine", J. Med. Chem., 1997, 40:3091-3099, Pentapharm Ltd.					
	A29	Young et al., "Development of a new physicochemical model for brain penetration and its application to the Design of centrally acting H ₂ receptor histamine antagonist", J. Med. Chem. 1988, 31:656-671, Smith Kline & French Research Ltd.					
D.K.	A30	Vollinga, "New ligands of the histamine H ₃ receptor", Synthesis, Structure activity relationships and molecular Pharmacology, pp: 7-210, 1995, Leiden/Amsterdam center for drug research					

EXAMINER

Barret K

DATE CONSIDERED

11/14/01

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.